Results 11 to 20 of about 7,681 (214)

Safety of tiotropium: Indirect evidence suggests the Respimat inhaler is riskier than the Handihaler [PDF]

BMJ, 2011
C. J. Cates, Cates, CJ
core   +3 more sources

Tiotropium HandiHaler® in the treatment of COPD: A safety review

International Journal of COPD, 2009
Steven Kesten1, Bart Celli2, Marc Decramer3, Inge Leimer4, Donald Tashkin51Boehringer Ingelheim Pharmaceuticals; Ridgefield, CT, USA; 2Caritas St. Elizabeth’s Medical Center, Boston, MA, USA; 3University of Leuven, Leuven, Belgium; 4Boehringer ...
Steven Kesten, Bart Celli, Marc Decramer, et al   +3 more
doaj   +1 more source

Effects of tiotropium on sympathetic activation during exercise in stable chronic obstructive pulmonary disease patients

International Journal of COPD, 2012
Kenji Yoshimura, Ryoji Maekura, Toru Hiraga, Seigo Kitada, Keisuke Miki, Mari Miki, Yoshitaka TateishiDepartment of Respiratory Medicine, Toneyama National Hospital, Osaka, JapanBackground: Tiotropium partially relieves exertional dyspnea and reduces the
Kitada S, Hiraga T, Maekura R, Yoshimura K, Tateishi Y, Miki M, Miki K   +6 more
doaj   +1 more source

Identifying Drugs Associated With Parkinson's Disease Risk Using Machine Learning. [PDF]

Basic Clin Pharmacol Toxicol
ABSTRACT Machine learning (ML)–based methods have been proposed as a potential approach for identifying candidate drugs to be repurposed as disease‐modifying treatments for Parkinson's disease (PD). We applied an ML‐based signal detection method to identify drugs associated with PD and evaluated the method's generalizability.
Pylkkö E, Courtois É, Paakinaho A, Hartikainen S, Kaasinen V, Elbaz A, Thiébaut ACM, Ahmed I, Tolppanen AM.   +8 more
europepmc   +2 more sources

Clinical predictors of treatment response to tiotropium add-on therapy in adult asthmatic patients: From multicenter real-world cohort data in Korea

World Allergy Organization Journal, 2022
Background: Tiotropium, a long-acting muscarinic antagonist, is recommended for add-on therapy to inhaled corticosteroids (ICS)-long-acting beta 2 agonists (LABA) for severe asthma.
Ji-Su Shim, MD, PhD, Juhae Jin, MA, Sae-Hoon Kim, MD, PhD, Taehoon Lee, MD, PhD, An-Soo Jang, MD, PhD, Chan Sun Park, MD, PhD, Jae-Woo Jung, MD, PhD, Jae-Woo Kwon, MD, PhD, Ji-Yong Moon, MD, PhD, Min-Suk Yang, MD, PhD, Jaechun Lee, MD, PhD, Jeong-Hee Choi, MD, PhD, Yoo Seob Shin, MD, PhD, Hee-Kyoo Kim, MD, PhD, Sujeong Kim, MD, PhD, Joo-Hee Kim, MD, PhD, Sang-Heon Cho, MD, PhD, Young-Hee Nam, MD, PhD, Sang-Hoon Kim, MD, PhD, So Young Park, MD, PhD, Gyu Young Hur, MD, PhD, Sang-Ha Kim, MD, PhD, Hye-Kyung Park, MD, PhD, Hyun Jung Jin, MD, PhD, Jae-Hyun Lee, MD, PhD, Jung-Won Park, MD, PhD, Ho Joo Yoon, MD, PhD, Byoung Whui Choi, MD, PhD, Young-Joo Cho, MD, PhD, Min-Hye Kim, MD, PhD, Tae-Bum Kim, MD, PhD   +30 more
doaj   +1 more source

UK-specific cost-effectiveness of tiotropium + olodaterol fixed-dose combination versus other LAMA + LABA combinations in patients with COPD

ClinicoEconomics and Outcomes Research, 2016
Abigail Tebboth,1 Andrew Ternouth,1 Nuria Gonzalez-Rojas2 1Boehringer Ingelheim Ltd., Bracknell, UK; 2Boehringer Ingelheim GmBH, Ingelheim, Germany Objective: The aim of this study is to assess the cost-effectiveness of other long-acting muscarinic ...
Tebboth A, Ternouth A, Gonzalez-Rojas N
doaj   +1 more source

Cost-effectiveness of the fixed-dose combination tiotropium/olodaterol versus tiotropium monotherapy or a fixed-dose combination of long-acting β2-agonist/inhaled corticosteroid for COPD in Finland, Sweden and the Netherlands: a model-based study

BMJ Open, 2021
Objectives Chronic obstructive pulmonary disease (COPD) guidelines advocate treatment with combinations of long-acting bronchodilators for patients with COPD who have persistent symptoms or continue to have exacerbations while using a single ...
Maureen Rutten-van Mölken, Martine Hoogendoorn, Isaac Corro Ramos, Stéphane Soulard, Jennifer Cook, Erkki Soini, Emma Paulsson   +6 more
doaj   +1 more source

Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study. [PDF]

PLoS ONE, 2015
This study assessed the long-term safety and efficacy of tiotropium Respimat, a long-acting inhaled anticholinergic bronchodilator, in asthma, added on to inhaled corticosteroids (ICS) with or without long-acting β2-agonist (LABA).285 patients with ...
Ken Ohta, Masakazu Ichinose, Yuji Tohda, Michael Engel, Petra Moroni-Zentgraf, Satoko Kunimitsu, Wataru Sakamoto, Mitsuru Adachi   +7 more
doaj   +1 more source

Tiotropium bromide [PDF]

International Journal of COPD, 2006
Therapy with bronchodilators forms the pharmacologic foundation of the treatment of patients with COPD. Bronchodilators can significantly lessen dyspnea, increase airflow, improve quality of life, and enhance exercise performance. While bronchodilators decrease airway resistance and lessen dynamic hyperinflation in patients with COPD, they have not ...
openaire   +3 more sources

Effect of tiotropium inhaler use on mortality in patients with tuberculous destroyed lung: based on linkage between hospital and nationwide health insurance claims data in South Korea

Respiratory Research, 2019
Background Although bronchodilator inhaler therapy can improve lung function in patients with tuberculous destroyed lung (TDL), its effect on mortality has not been studied.
Ho Cheol Kim, Tae Hoon Kim, Ye-Jee Kim, Chin Kook Rhee, Yeon-Mok Oh   +4 more
doaj   +1 more source